You are viewing the site in preview mode

Skip to main content

Advertisement

Table 7 Meta-analyses of long-term clinical outcomes in patients with SVR

From: Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits

Study Details Outcomes assessed Key findings
Almasio et al. 2003 [107] Systematic review and pooled analysis (N = 1,031 patients for cirrhosis analysis, N = 3,914 patients for HCC analysis) HCC, progression to cirrhosis Risk reduction for progression to cirrhosis for SVR versus no SVR = −0.22 (−0.36 to −0.08). Risk reduction for HCC = −0.097 (−0.13 to −0.07)
Kimer et al. 2012 [51] Systematic review and meta-analysis of 8 RCTs and 5 prospective studies (N = 3,208 patients); random effects model used. Patients treated with IFN, pegIFN or PegIFN plus ribavirin HCC RR (95% for HCC for SVR versus no intervention = 0.15 (0.05–0.45)
Morgan et al. 2013 [53] Systematic review and meta-analysis of 30 studies (N = 31,528 patients) HCC For patients at all stages of disease HR (95% CI) for HCC for SVR versus non-response = 0.24 (0.18–0.31) (p < 0.001)
(18 studies included in meta-analysis) investigating impact of treatment on risk for HCC
For patients with advanced liver disease HR (95% CI) for HCC for SVR versus non-response = 0.23 (0.16–0.35) (p < 0.001)
Singal et al. 2010 [49] Systematic review and meta-analysis of 20 studies (N = 4,700 patients) in treatment-naïve patients treated with IFN or IFN plus ribavirin; random effects model used HCC RR (95% CI) for HCC for SVR versus non-responders = 0.35 (0.26–0.46)
Singal et al. 2010 [50] Systematic review and meta-analysis of 26 studies (N = 13,191 patients) HCC, hepatic decompensation, liver-related mortality RR (95% CI) for SVR versus treatment failure were: HCC 0.21 (0.16–0.27) (p = ns) for all patients and 0.27 (0.19–0.39) (p = ns) for patients with cirrhosis.
Liver-related mortality was 0.23 (0.10–0.52) (p = ns) for all patients and 0.13 (0.06–0.29) (p = ns) for patients with cirrhosis. RR (95% CI) Hepatic decompensation 0.16 (0.04–0.59) (p = ns) for all patients and 0.08 (0.03–0.21) (p = 0.02) for patients with cirrhosis
  1. CI, confidence interval; HCC, hepatocellular carcinoma; RCT, randomized controlled trial; RR, relative risk.